The three-year study involved 118 people age 85 and older with no memory problems. Half of the participants took ginkgo biloba extract three times a day and half took a placebo. During the study, 21 people developed mild memory problems, or questionable dementia: 14 of those took the placebo and seven took the ginkgo extract. Although there was a trend favoring ginkgo, the difference between those who took gingko versus the placebo was not statistically significant.
The researchers made an interesting observation when they examined the data at the end of the trial. Taking into account whether people followed directions in taking the study pills, they found that people who reliably took the supplement had a 68 percent lower risk of developing mild memory problems than those who took the placebo. Without further study, it is unclear if this difference is real or just a chance occurrence.
On a cautionary note, the study also found that people taking ginkgo biloba were more likely to have a stroke or transient ischemic attack, or mini stroke. Seven people taking ginkgo had strokes, while none of those taking placebo did. “Ginkgo has been reported to cause bleeding-related complications, but the strokes in this case were due to blood clots, not excessive bleeding, and were generally not severe,” said study author Hiroko Dodge, PhD, of the Department of Public Health and Center for Healthy Aging Research at Oregon State University in Corvallis.
“These results need to be clarified with larger studies, but the findings are interesting because ginkgo biloba is already widely used, readily available, and relatively inexpensive,” said Dodge. “One of the most pressing public health problems facing our society is the rapidly growing number of people who, due to their age alone, are at high risk of developing dementia. The potential to delay or prevent this is of great importance. Further studies are needed to determine whether gingko biloba has any benefits in preventing cognitive decline and whether it is safe.”
Dodge noted that this is the first randomized, controlled trial of prevention of dementia in people age 85 and older.
The research was conducted at Oregon Health & Science University’s NIA-Layton Aging & Alzheimer’s Disease Center and the Oregon Center for Complementary and Alternative Medicine in Neurological Disorders. The study was supported by grants from the National Institute on Aging and the National Center for Complementary and Alternative Medicine (NCCAM). The ginkgo biloba extract was provided by Thorne Research, Inc.
The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as epilepsy, dystonia, migraine, Huntington’s disease, and dementia.
What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Health and Medicine
06.12.2016 | Life Sciences
05.12.2016 | Power and Electrical Engineering